

## New Hampshire Medicaid Fee-for-Service Program Weight Management Criteria

Approval Date: January 14, 2022

### Medications

Brand Names	Generic Names	Dosage
Adipex-P®	phentermine	37.5 mg
Contrave®	naltrexone/bupropion	8 mg naltrexone/90 mg bupropion
Imcivree™	setmelanotide	10 mg/mL
Lomaira™	phentermine	8 mg
	phentermine	15 mg, 30 mg, 37.5 mg
Qsymia®	phentermine/topiramate	3.75/23 mg, 7.5/46 mg, 11.25/69 mg, 15/92 mg
Saxenda®	liraglutide	0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, 3 mg (6 mg/mL, 3 mL)
Wegovy®	semaglutide	0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL
Xenical®	orlistat	120 mg

### Criteria for Approval

Requests for Imcivree™ see below.

1. Patient must be  $\geq 12$  years old (Saxenda®, Xenical®),  $\geq 16$  years old (Adipex®, phentermine, Lomaira™) or  $\geq 18$  years old (Contrave®, Qsymia®, Wegovy®); **AND**
2. Documented failure of at least a three-month trial on a low-calorie diet (1,200 kcal/day for women, 1,600 kcal/day for men); **AND**
3. A regimen of increased physical activity unless medically contraindicated by co-morbidity; **AND**
4. Baseline body mass index (BMI) must be:
  - a.  $\geq 30$  kg/m<sup>2</sup> with no risk factors; **OR**
  - b.  $\geq 27$  kg/m<sup>2</sup> with at least one very high-risk factor; **OR**
5. Waist circumference must be  $> 102$  cm for men and  $> 88$  cm for women with at least one very high-risk factor; **OR**

Proprietary & Confidential

© 2003–2022 Magellan Health, Inc. All rights reserved.

Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc.

6. At least two other risk factors (see Table 1); **AND**
7. No contraindications (disease state or current therapy) should exist unless the prescriber documents that benefits outweigh risks (see Table 2).

Table 1: Risk Factors	
Very high risk	<ul style="list-style-type: none"> <li>▪ Type 2 diabetes</li> <li>▪ Established coronary heart disease</li> <li>▪ Other atherosclerotic disease</li> <li>▪ Sleep apnea</li> </ul>
Other risk factors	<ul style="list-style-type: none"> <li>▪ Hypertension</li> <li>▪ Dyslipidemia</li> <li>▪ Impaired fasting glucose concentration</li> <li>▪ Cigarette smoking</li> <li>▪ Family history of premature heart disease</li> <li>▪ Age (men &gt; 45 years, women &gt; 55 years or postmenopausal)</li> <li>▪ Gynecologic abnormalities</li> <li>▪ Osteoarthritis</li> <li>▪ Gallstones</li> <li>▪ Stress incontinence</li> </ul>

Table 2: Contraindications, Precautions, and Drug Interactions			
Drug	Contraindications	Precautions	Drug Interactions
<b>orlistat</b>	<ul style="list-style-type: none"> <li>▪ Chronic malabsorption syndrome</li> <li>▪ Cholestasis</li> <li>▪ Pregnancy</li> </ul>	<ul style="list-style-type: none"> <li>▪ Hx of hyperoxaluria or Ca oxalate nephrolithiasis</li> <li>▪ Patients with deficiency of any fat-soluble vitamins</li> </ul>	
<b>phentermine</b>	<ul style="list-style-type: none"> <li>▪ Hx of glaucoma</li> <li>▪ Hx of hypertension (moderate to severe)</li> <li>▪ Hx of hyperthyroidism</li> <li>▪ Hx of cardiovascular disease</li> </ul>	<ul style="list-style-type: none"> <li>▪ Hx of drug abuse</li> <li>▪ Hx of anxiety disorders</li> <li>▪ Hx of diabetes mellitus</li> <li>▪ Hx of hypertension (mild)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Monoamine oxidase inhibitors (MAOI): contraindicated</li> </ul>
<b>phentermine/ topiramate</b>	<ul style="list-style-type: none"> <li>▪ Pregnancy</li> <li>▪ Glaucoma</li> <li>▪ Hyperthyroidism</li> </ul>	<ul style="list-style-type: none"> <li>▪ Increase in heart rate</li> <li>▪ Suicidal behavior and ideation</li> <li>▪ Acute myopia and secondary angle closure glaucoma</li> </ul>	<ul style="list-style-type: none"> <li>▪ MAOI</li> <li>▪ Oral contraceptive</li> <li>▪ Non-potassium sparing diuretic</li> <li>▪ CNS depressants including alcohol</li> </ul>
<b>naltrexone/bupropion</b>	<ul style="list-style-type: none"> <li>▪ Uncontrolled hypertension</li> </ul>	<ul style="list-style-type: none"> <li>▪ Suicidal thoughts and ideation</li> </ul>	<ul style="list-style-type: none"> <li>▪ MAOI</li> </ul>

**Table 2: Contraindications, Precautions, and Drug Interactions**

Drug	Contraindications	Precautions	Drug Interactions
	<ul style="list-style-type: none"> <li>▪ Seizure disorders</li> <li>▪ Anorexia nervosa or bulimia</li> <li>▪ Undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs</li> <li>▪ Chronic opioid use</li> </ul>		<ul style="list-style-type: none"> <li>▪ Opioid analgesics</li> <li>▪ Concurrent use of other bupropion-containing products if the total daily dose of all bupropion-containing products is above the FDA maximum recommended dose</li> </ul>
<b>liraglutide</b>	<ul style="list-style-type: none"> <li>▪ Pregnancy</li> <li>▪ Personal or family Hx of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2</li> </ul>	<ul style="list-style-type: none"> <li>▪ Suicidal behavior and ideation</li> <li>▪ Acute pancreatitis</li> <li>▪ Acute gallbladder disease</li> <li>▪ Renal impairment</li> </ul>	<ul style="list-style-type: none"> <li>▪ GLP-1 receptor agonist</li> <li>▪ Insulins</li> </ul>
<b>semaglutide</b>	<ul style="list-style-type: none"> <li>▪ Personal or family Hx of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2</li> </ul>	<ul style="list-style-type: none"> <li>▪ Suicidal behavior and ideation</li> <li>▪ Acute pancreatitis</li> <li>▪ Acute gallbladder disease</li> <li>▪ Renal impairment</li> </ul>	<ul style="list-style-type: none"> <li>▪ GLP-1 receptor agonist</li> <li>▪ Insulins</li> </ul>

**Criteria for Approval (Imcivree™ only)**

1. Patient must be ≥ 6 years of age; **AND**
2. Baseline BMI must be ≥ 30 kg/m<sup>2</sup> **or** ≥ 95th percentile on pediatric growth chart; **AND**
3. Patient has proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency, as confirmed by a genetic test; **AND**
4. Genetic variants are interpreted as pathogenic, likely pathogenic, or of uncertain significance; **AND**
5. Prescribed by or in consultation with an endocrinologist or geneticist.

## Criteria for Renewal

Renewal requests for Imcivree™ see below.

1. Ongoing prescriber documentation of adherence to a low-calorie diet (1,200 kcal/day for women, 1,600 kcal/day for men); **AND**
2. A regimen of increased physical activity (unless medically contraindicated by co-morbidity) during anti-obesity therapy; **AND**
3. No contraindications (disease state or current therapy) should exist, unless prescriber documents that benefits outweigh risks (see Table 2); **AND**
4. See **Special Approval Instructions** below for weight loss requirements.

## Special Approval Instructions

1. First approval will be for three months.
2. After three months of therapy, for three-month renewal, patient must have lost at least 4 lb. in the first month and 1 lb./month for second and third month.
3. After six months of therapy, a six-month approval may be granted if a 5% weight reduction has been achieved.
4. After one year of therapy, additional six-month approvals may be granted if a 10% weight reduction has been achieved **AND** the patient continues to maintain weight loss.
5. After lapses of therapy, additional trials may be approved if criteria requirements are met.
6. Phentermine may not be approved for therapy beyond nine months.
7. Xenical® may not be approved for therapy beyond four years.

## Criteria for Renewal (Imcivree™ only)

1. First approval will be for four months; **AND**
2. After four months of therapy, patient must have lost at least 5% of the baseline body weight (or  $\geq 5\%$  of baseline BMI in those with continued growth potential); **AND**
3. The patient has not experienced treatment-limiting adverse reactions (e.g., gastrointestinal intolerability below labeled dosing for age, sexual adverse effects, depression, or suicidal ideation).

## Criteria for Denial

Prior approval will be denied if the approval criteria are not met.

## References

Available upon request.

## Revision History

Reviewed by	Reason for Review	Date Approved
Pharmacy and Therapeutic Committee	New	09/2001
Pharmacy and Therapeutic Committee	Pursuant to Chapter 281, NH law 2001	10/2002
Pharmacy and Therapeutic Committee	Revision	03/24/2005
Commissioner	Approval	04/15/2005
Pharmacy and Therapeutic Committee	Revision	04/16/2009
Commissioner	Approval	05/12/2009
DUR Board	Revision	06/18/2012
Commissioner	Approval	07/10/2012
	New drug to market	09/02/2014
DUR Board	Revision	05/12/2015
Commissioner	Approval	06/30/2015
DUR Board	Revision	05/31/2016
Commissioner	Approval	06/18/2016
DUR Board	Revision	03/20/2017
Commissioner	Approval	06/08/2017
DUR Board	Revision	03/12/2019
Commissioner Designee	Approval	04/05/2019
DUR Board	Revision	06/30/2020
Commissioner Designee	Approval	08/07/2020
DUR Board	Revision	12/15/2020
Commissioner	Approval	02/24/2021
DUR Board	Revision	12/02/2021
Commissioner Designee	Approval	01/14/2022